- Home
- ZTEK vs FBIO Comparison
ZTEK vs FBIO Comparison
Compare ZTEK & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZTEK | FBIO |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.3M | 88.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZTEK | FBIO |
|---|---|---|
| Price | $0.71 | $2.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 41.1K | ★ 337.7K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $657,134.00 | ★ $62,303,000.00 |
| Revenue This Year | N/A | $29.71 |
| Revenue Next Year | N/A | $49.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2225.73 | N/A |
| 52 Week Low | $0.62 | $1.33 |
| 52 Week High | $1.84 | $4.20 |
Technical Indicators
Market Signals| Indicator | ZTEK | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 61.11 |
| Support Level | $0.70 | $2.49 |
| Resistance Level | $0.75 | $3.00 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 12.50 | 92.23 |
Price Performance
Historical ComparisonAbout ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.